InnoCare Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	7,072	6,241	8,287	8,698	5,929
Trading Asset Securities	-	759.18	-	313.29	317.06
Cash & Short-Term Investments	7,072	7,000	8,287	9,011	6,246
Cash Growth	1.03%	-15.53%	-8.04%	44.28%	57.34%
Accounts Receivable	502.88	351	276.38	127.83	45.27
Other Receivables	0	0.05	31.34	61.79	62.27
Receivables	502.88	351.05	307.71	189.61	107.55
Inventory	162.87	95.58	119.09	65.32	9.92
Other Current Assets	324.09	373.56	51.38	33.56	53.87
Total Current Assets	8,062	7,820	8,765	9,300	6,417
Property, Plant & Equipment	752.26	814.27	798.5	937.27	566.08
Long-Term Investments	1,201	0.4	5.66	11.71	326.1
Goodwill	3.12	3.12	3.12	3.13	3.13
Other Intangible Assets	248.05	258.14	266.03	41.31	34.17
Long-Term Deferred Charges	30.31	31.94	33.3	-	-
Other Long-Term Assets	526.24	479.43	48.06	28.04	50.95
Total Assets	10,824	9,407	9,920	10,321	7,398
Accounts Payable	183.7	128.36	134.9	118.6	84.6
Accrued Expenses	137.6	87.69	100.08	116.03	97.5
Short-Term Debt	176.93	137.45	-	-	-
Current Portion of Long-Term Debt	112.26	56.35	1,256	1,197	-
Current Portion of Leases	27.23	31.61	23.23	20.11	20.34
Current Income Taxes Payable	11.88	-	-	-	-
Current Unearned Revenue	105.43	-	-	12	19.48
Other Current Liabilities	628.72	607.82	567.64	611.52	107.39
Total Current Liabilities	1,384	1,049	2,082	2,075	329.3
Long-Term Debt	1,276	1,322	331.88	287.76	1,238
Long-Term Leases	19.03	27.44	43.65	35.44	47.44
Long-Term Unearned Revenue	289.42	263	281.78	278.2	123.61
Long-Term Deferred Tax Liabilities	106.51	-	-	-	-
Total Liabilities	3,074	2,662	2,739	2,677	1,739
Common Stock	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	12,199	12,111	12,150	11,756	9,372
Retained Earnings	-4,878	-5,520	-5,080	-4,423	-3,536
Treasury Stock	-19.75	-3.1	-	-	-
Comprehensive Income & Other	425.12	137.99	77.23	263.73	-230.85
Total Common Equity	7,727	6,725	7,148	7,597	5,605
Minority Interest	22.35	20.63	32.86	47.23	54.36
Shareholders' Equity	7,749	6,746	7,181	7,644	5,659
Total Liabilities & Equity	10,824	9,407	9,920	10,321	7,398
Total Debt	1,611	1,575	1,655	1,540	1,306
Net Cash (Debt)	5,461	5,425	6,632	7,471	4,940
Net Cash Growth	0.66%	-18.20%	-11.22%	51.24%	76.67%
Net Cash Per Share	3.23	3.20	3.89	5.05	3.62
Filing Date Shares Outstanding	1,932	1,694	1,690	1,682	1,410
Total Common Shares Outstanding	1,932	1,694	1,690	1,682	1,410
Working Capital	6,678	6,771	6,683	7,224	6,088
Book Value Per Share	4.00	3.97	4.23	4.52	3.98
Tangible Book Value	7,476	6,464	6,879	7,553	5,567
Tangible Book Value Per Share	3.87	3.81	4.07	4.49	3.95
Buildings	-	-	364.63	224.41	81.04
Machinery	405.49	362.86	302.01	248.13	127.57
Construction In Progress	115.01	138.86	166.91	197.65	230.72
Leasehold Improvements	-	-	-	35.44	6.68

Source: S&P Global Market Intelligence. Standard template. Financial Sources.